Range Low Price High Price Comment
30 days $1.58 $5.85 Wednesday, 1st May 2024 CTMX stock ended at $5.13. This is 214.72% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 110.43% from a day low at $2.78 to a day high of $5.85.
90 days $1.38 $5.85
52 weeks $1.04 $5.85

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Feb 03, 2016 $16.08 $16.93 $15.32 $15.68 81 000
Feb 02, 2016 $15.64 $16.00 $14.51 $16.00 86 900
Feb 01, 2016 $15.40 $16.45 $14.61 $15.86 61 000
Jan 29, 2016 $15.22 $16.01 $14.51 $15.71 74 400
Jan 28, 2016 $15.12 $15.67 $14.26 $15.18 45 600
Jan 27, 2016 $16.16 $16.88 $14.43 $15.10 112 000
Jan 26, 2016 $14.90 $16.65 $14.54 $16.23 69 600
Jan 25, 2016 $13.98 $14.99 $13.84 $14.65 144 000
Jan 22, 2016 $14.97 $15.41 $13.11 $14.00 38 200
Jan 21, 2016 $14.59 $15.58 $14.39 $14.46 79 400
Jan 20, 2016 $12.13 $15.45 $12.13 $14.84 116 100
Jan 19, 2016 $13.50 $15.39 $12.25 $12.61 47 100
Jan 15, 2016 $13.59 $14.45 $12.81 $13.25 24 900
Jan 14, 2016 $14.54 $15.20 $13.38 $14.05 45 300
Jan 13, 2016 $15.53 $17.20 $14.21 $14.36 113 900
Jan 12, 2016 $14.72 $15.69 $14.35 $15.50 74 100
Jan 11, 2016 $14.17 $15.10 $13.71 $14.32 93 900
Jan 08, 2016 $15.69 $16.00 $13.69 $14.21 90 700
Jan 07, 2016 $16.80 $17.64 $15.27 $15.52 98 400
Jan 06, 2016 $19.03 $19.67 $16.80 $16.97 82 800
Jan 05, 2016 $20.48 $20.56 $19.07 $19.43 73 400
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT